Published in Dig Dis Sci on April 08, 2016
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet (2001) 35.17
The quality of care. How can it be assessed? JAMA (1988) 24.47
The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol (2006) 10.21
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med (2014) 9.45
Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology (2002) 9.35
Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med (1999) 6.50
Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology (2010) 3.35
Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol (2005) 3.09
Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries. Clin Infect Dis (2014) 2.80
Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med (2013) 2.46
Natural killer cell dynamic profile is associated with treatment outcome in patients with chronic HCV infection. J Hepatol (2013) 2.19
Evaluation of liver disease progression in the German hepatitis C virus (1b)-contaminated anti-D cohort at 35 years after infection. Hepatology (2013) 2.13
Extraction of semantic biomedical relations from text using conditional random fields. BMC Bioinformatics (2008) 2.12
Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology (2009) 2.07
The risk of long-term morbidity and mortality in patients with chronic hepatitis C: results from an analysis of data from a Department of Veterans Affairs Clinical Registry. JAMA Intern Med (2014) 2.05
A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol (2009) 1.86
Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology (2002) 1.79
Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. Am J Gastroenterol (2012) 1.55
Pegylated IFN-α regulates hepatic gene expression through transient Jak/STAT activation. J Clin Invest (2014) 1.54
HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV. Hepatology (2014) 1.46
Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response. Hepatology (2003) 1.39
Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications. J Viral Hepat (2007) 1.21
Effect of hepatitis C virus and its treatment on survival. Hepatology (2009) 1.20
Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C. Hepatology (1997) 1.18
Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971 to 1975. Hepatology (2000) 1.12
Long-term beneficial effects in sustained responders to interferon-alfa therapy for chronic hepatitis C. J Hepatol (2001) 1.09
Hepatitis C virus infection: the new global epidemic. Expert Rev Anti Infect Ther (2005) 1.08
Importance of patient, provider, and facility predictors of hepatitis C virus treatment in veterans: a national study. Am J Gastroenterol (2010) 1.03
Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C. J Hepatol (2013) 1.03
Hepatitis C treatment candidacy and outcomes among 4318 US veterans with chronic hepatitis C virus infection: does a history of injection drug use matter? J Clin Gastroenterol (2007) 0.99
Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. Hepatology (2011) 0.98
Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C. Intervirology (2007) 0.94
Meta-analysis: re-treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy. Aliment Pharmacol Ther (2010) 0.88
NK cells, innate immunity and hepatitis C infection after liver transplantation. Clin Infect Dis (2011) 0.86
The epidemiology and clinical characteristics of patients with newly diagnosed alcohol-related liver disease: results from population-based surveillance. J Clin Gastroenterol (2010) 0.85
Treatment eligibility and outcomes in elderly patients with chronic hepatitis C: results from the VA HCV-001 Study. Dig Dis Sci (2007) 0.85
Nonresponse to interferon-α based treatment for chronic hepatitis C infection is associated with increased hazard of cirrhosis. PLoS One (2013) 0.83
Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C. Cochrane Database Syst Rev (2013) 0.82
After the cure: management of HCV after achievement of SVR. Curr HIV/AIDS Rep (2013) 0.80
Frontiers in the treatment of hepatitis C virus infection. Gastroenterol Hepatol (N Y) (2014) 0.79
Hepatitis C virus infection in the elderly: epidemiology, natural history and management. Drugs Aging (2008) 0.78
Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C. Am J Gastroenterol (2012) 0.78